Experience. Commitment. Results.
KindlyMD, Inc. (NASDAQ: KDLY), relating to the proposed merger with Nakamoto Holdings Inc. Under the terms of the agreement, Nakamoto will continue as the surviving entity, with shares of KindlyMD common stock being converted into shares of common stock of the surviving corporation.
TaskUs, Inc. (NASDAQ: TASK), relating to the proposed merger with an affiliate of Blackstone. Under the terms of the agreement, the affiliate will acquire 100% of the outstanding shares of Class A common stock they do not already own for $16.50 per share.
Hall of Fame Resort & Entertainment Company (NYSE: PHX), relating to the proposed merger with WhiteHawk Income Corporation. Under the terms of the agreement, WhiteHawk will acquire PHX in an all-cash transaction that values PHX at $4.35 per share.
Hall of Fame Resort & Entertainment Company (NASDAQ: HOFV), relating to the proposed merger with HOFV Holdings, LLC, an affiliate of Industrial Realty Group, LLC. Under the terms of the agreement, the Investor will acquire all outstanding shares of the Company’s common stock not currently owned by IRG and its affiliates for $0.90 per share … Read more
Asset Entities Inc. (NASDAQ: ASST), relating to the proposed merger with Strive Asset Management. Under the terms of the agreement, legacy shareholders of Asset Entities will own 5.8% of the public company, prior to factoring in the contemplated Bitcoin-for-stock exchange and any additional financing.
AvidXchange Holdings, Inc. (NASDAQ: AVDX), relating to the proposed merger with TPG and Corpay. Under the terms of the agreement, TPG and Corpay will acquire AvidXchange for $10.00 per share in cash.
FARO Technologies, Inc. (NASDAQ: FARO), relating to the proposed merger with AMETEK, Inc. Under the terms of the agreement, AMETEK will acquire all outstanding shares of FARO Technologies common stock for $44 per share in cash.
Kronos Bio, Inc. (NASDAQ: KRON), relating to the proposed merger with Concentra Biosciences, LLC. Under the terms of the agreement, Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common stock, plus one non-tradeable contingent value right.
Regulus Therapeutics Inc. (NASDAQ: RGLS), relating to the proposed merger with Novartis AG. Under the terms of the agreement, Novartis will acquire Regulus for an initial payment of $7.00 per share, plus a non-tradeable CVR for $7.00 per share payable upon the achievement of a milestone in respect to regulatory approval.
GSR III Acquisition Corp. (NASDAQ: GSRT), relating to the proposed merger with Terra Innovatum Srl. Under the terms of the agreement, Terra Innovatum shareholders will roll 100% of their equity into the newly formed public entity.